Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) Net Margin (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Net Margin data on record, last reported at 29.5% in Q3 2025.

  • For Q3 2025, Net Margin rose 28081.0% year-over-year to 29.5%; the TTM value through Dec 2025 reached 162.85%, up 14687.0%, while the annual FY2025 figure was 162.85%, 14686.0% up from the prior year.
  • Net Margin reached 29.5% in Q3 2025 per TNGX's latest filing, up from 1220.31% in the prior quarter.
  • Across five years, Net Margin topped out at 29.5% in Q3 2025 and bottomed at 1220.31% in Q2 2025.
  • Average Net Margin over 5 years is 411.74%, with a median of 419.8% recorded in 2022.
  • Peak YoY movement for Net Margin: skyrocketed 29055bps in 2023, then plummeted -109175bps in 2025.
  • A 5-year view of Net Margin shows it stood at 385.69% in 2021, then decreased by -18bps to 453.28% in 2022, then dropped by -25bps to 566.19% in 2023, then crashed by -62bps to 914.79% in 2024, then soared by 103bps to 29.5% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 29.5% in Q3 2025, 1220.31% in Q2 2025, and 738.91% in Q1 2025.